Lucid Diagnostics (LUCD) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $1.2M, a 20% sequential and 50% year-over-year increase, driven by robust EsoGuard test volume and commercial execution.

• Completed a comprehensive clinical evidence package for EsoGuard, including multiple peer-reviewed validation studies, positioning for Medicare and commercial coverage.

• Expanded commercial focus to direct contracting, concierge medicine, and employer markets, with new programs and experienced hires to drive growth.

• Met with CMS Medicare Administrative Contractor to discuss upcoming Medicare coverage submission.

• Substantial doubt exists about the ability to continue as a going concern without additional capital or significant revenue growth.

Financial highlights

• Q3 2024 revenue was $1.2M, up $0.4M year-over-year; operating expenses were $12.9M, and GAAP net loss was $12.4M ($0.25/share).

• Non-GAAP adjusted loss for Q3 2024 was $10.1M ($0.20/share), flat sequentially.

• Cash at September 30, 2024, was $14.5M; subsequent financing increases pro forma cash to $28M, providing nearly three quarters of runway at current burn rate.

• Quarterly burn rate was $10.4M, consistent with prior quarters.

• Weighted average shares outstanding (Q3 2024): 50.4M; shares outstanding at September 30, 2024: 51.6M, with potential for significant dilution if all preferred shares convert.

Outlook and guidance

• Poised to submit data to MolDX for Medicare coverage, with optimism for a first-half 2025 decision.

• Expect continued robust test volume and revenue growth, with Q4 off to a strong start and a robust pipeline of direct contracting events.

• Continued recurring losses and negative cash flow from operations are expected in the near term.

• Ability to continue operations depends on raising additional capital and achieving substantial revenue growth.

• Anticipate broader commercial coverage following Medicare approval, targeting both Medicare and commercial payer populations.